Results 201 to 210 of about 59,754 (305)

Cationic Nanogel Coated Norovirus VLP Nasal Vaccine Induces Neutralizing Mucosal IgA and Serum IgG Antibodies. [PDF]

Mol Pharm
Yuki Y, Kurokawa S, Yamanoue T, Tsuchihashi T, Tamiya S, Sawada SI, Uchida Y, Sugiura K, Nakahashi-Ouchida R, Sakon N, Tokuhara D, Akiyoshi K, Sato S, Kiyono H.   +13 more
europepmc   +1 more source

Organising Inequality: Viral Contamination of Healthcare Policies During the COVID‐19 Pandemic in Wales

Transactions of the Institute of British Geographers, Volume 51, Issue 2, June 2026.
ABSTRACT This article explores the role of the COVID‐19 virus in changing healthcare policies in Wales and their effects on pandemic inequalities. It draws on the analysis of policy documents and key informant interviews with government and healthcare officials in Wales conducted during the cross‐European study on the varying impacts of pandemic ...
Sergei Shubin, Diana Beljaars
wiley   +1 more source

Research advances in chikungunya virus: Epidemiology, pathogenesis, and control. [PDF]

One Health
Dai S, Li H, Li S, Shao X, Cheng X.
europepmc   +1 more source

Inhibitors Targeting SARS‐CoV‐2 Papain‐Like Protease: Screening, Design, Synthesis, and Biological Evaluation

ChemMedChem, Volume 21, Issue 9, 14 May 2026.
In our study, we obtained both non‐covalent and covalent PLpro inhibitors. Additionally, the stable protein‐ligand interactions of the active compound were examined using advanced computational docking and molecular dynamics simulations. The non‐covalent inhibitor 2t showed antiviral activity with an EC50 of 2.89 µM, indicating its potential as a ...
Elena‐Oriana Iuga, Nilu Gone, Mariana Ortiz de Godoy, Gabriel Correa Verissimo, Giovanna de Jesus Agostinetto, Liam Urich, Nadine Krüger, Thales Kronenberger, Rafael Victorio Carvalho Guido, Anthony J. O’Donoghue, Stefan A. Laufer, Thanigaimalai Pillaiyar   +11 more
wiley   +1 more source

Susceptibility of naturally human papillomavirus type 16 major capsid protein L1 variants to vaccines and predictions of future evolutionary trends. [PDF]

Tumour Virus Res
Yu D, Wang J, Li Y, Wang H, Zhang J, Wang M, Li H, Zhang L, Zhu N, Lu X, Wang S.   +10 more
europepmc   +1 more source

Lipid Nanoparticles for the Delivery of CRISPR/Cas9 Machinery to Enable Site‐Specific Integration of CFTR and Mutation‐Agnostic Disease Rescue

Advanced Functional Materials, Volume 36, Issue 36, 4 May 2026.
Lipid nanoparticles (LNPs) are optimized to co‐deliver Cas9‐encoding messenger RNA (mRNA), a single guide RNA (sgRNA) targeting the endogenous cystic fibrosis transmembrane conductance regulator (CFTR) gene, and homologous linear double‐stranded donor DNA (ldsDNA) templates encoding CFTR.
Ruth A. Foley, Paul G. Ayoub, Vrishti Sinha, Colin Juett, Alicia Sanoyca, Emily C. Duggan, Lindsay E. Lathrop, Priyanka Bhatt, Kevin Coote, Beate Illek, Brigitte N. Gomperts, Donald B. Kohn, Steven J. Jonas   +12 more
wiley   +1 more source

A modular vaccine platform merging the rapid development of genetic vaccines with the immunogenicity of virus-like particles. [PDF]

Clin Transl Med
Sander AF, Fougeroux C.
europepmc   +1 more source

What Is Your Diagnosis? Abnormal WDF Scattergram From the Sysmex XN‐1000V in a Cat

Veterinary Clinical Pathology, EarlyView.
Javier Martínez‐Caro, Laura Chaves‐Falcón, Marta Lemos, Xavier Roura, Luis Bosch, Josep Pastor   +5 more
wiley   +1 more source

Safe and Localized Lentiviral Gene Delivery via Injectable Mesoporous Scaffolds for Potent Antitumor Immunity

Advanced Materials, Volume 38, Issue 25, 4 May 2026.
This work introduces an injectable mesoporous silica rod scaffold that confines lentiviral vectors to the injection site, enabling localized dendritic cell recruitment and transduction. The platform sustains antigen expression, promotes robust T‐cell activation, and enhances antitumor immunity.
Thanh Loc Nguyen, Yeon‐ju Kim, Jihye Im, Dong Kwang Min, Hyunsu Shin, Thuy An Trinh, Ngoc Man Phan, Min‐jeong Son, Ji‐yeon Shim, Ye‐lim Lee, Yujeong Ha, Kwang‐il Lim, Jaeyun Kim   +12 more
wiley   +1 more source

From bench to bedside: Unveiling the background and benefits of nanovaccines tested in clinics. [PDF]

Asian J Pharm Sci
Egorova VS, Kolesova EP, Voronina MV, Denisova ER, Syrocheva AO, Pallaeva T, Hakemi MG, Zamyatnin AA, Ivanov KI, Kostyushev D, Brezgin S, Kostyusheva A, Parodi A.   +12 more
europepmc   +1 more source